De-Risking Early-Stage Biotech: Turning Vision into Venture Capital

Unlock the Blueprint for Smart Biotech Investment Decisions

In today's capital-constrained biotech landscape, early-stage companies must do more than innovate – they must strategically de-risk. This insight brief from IQVIA Biotech reveals how to transform your scientific vision into a compelling investment case that resonates with venture capitalists.

Download the insight brief to learn:

How to Build a Strategic Target Product Profile (TPP)

Align clinical and commercial goals from day one
Create a dynamic, evolving vision that adapts with evidence
Use TPPs to differentiate in crowded markets and accelerate timelines

How to Design a Clinical Development Plan (CDP) That Attracts Capital

Model multiple development pathways with real-world data
Balance time, cost, and risk to optimize ROI
Communicate clearly with investors using scenario-based planning

How to Use Expected Net Present Value (eNPV) to Quantify Opportunity

Translate scientific uncertainty into investor-ready metrics
Compare development strategies with a single, objective value lens
Leverage scenario modeling to show trade-offs and upside potential

Whether you're preparing for Series A or planning your next round, this guide will help you:

Prioritize high-value indications
Align internal teams and external stakeholders
Build confidence with investors through robust, data-driven planning